Drug intelligence / Profile preview

morphine intranasal

Development stage: Phase 2
Lead developer: Pfizer
Modality: Small Molecules
Administration: Intranasal

Overview

MNS075 is a nasally administered formulation of morphine that was being developed for the treatment of postoperative pain. It works as an opioid mu receptor agonist. The drug was developed as a nasal spray for treating moderate to severe post-surgical pain, particularly following orthopedic procedures such as bunionectomy surgery.

Targets

KOR (Kappa opioid receptor)DOR (Opioid Receptor Delta 1)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on morphine intranasal.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on morphine intranasal.

Explore the full profile